Can I read Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status on EtoBox?

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status by Keung, Man Yee; Wu, Yanyuan; Badar, Francesca; Vadgama, Jaydutt V. is a Medicine article available to read on EtoBox.

What is Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status about?

Poly (ADP-ribose) polymerase inhibitors (PARPi) have proven to be beneficial to patients with metastatic breast cancer with BRCA1/2 (BReast CAncer type 1 and type 2 genes) mutations. However, certain PARPi in pre-clinical studies have been shown to inhibit cell growth and promote the death of breast cancer cells lacking mutations in BRCA1/2. Here, we examined the inhibitory potency of 13 different PARPi in 12 breast cancer cell lines with and without BRCA-mutations using cell viability assays. The results showed that 5 of the 8 triple-negative breast cancer (TNBC) cell lines were susceptible to PARPi regardless of the BRCA-status. The estrogen receptor (ER) negative/ human epidermal growth factor receptor 2 (HER2) positive (ER-/HER2+) cells, SKBR3 and JIMT1, showed high sensitivity to Talazoparib. Especially JIMT1, which is known to be resistant to trastuzumab, was responsive to Talazoparib at 0.002 μM. Niraparib, Olaparib, and Rucaparib also demonstrated effective inhibitory potency in both advanced TNBC and ER-/HER2+ cells with and without BRCA-mutations. In contrast, a BRCA-mutant TNBC line, HCC1937, was less sensitive to Talazoparib, Niraparib, Rucaparib, and not responsive to

Who reads Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status?

Author

Keung, Man Yee; Wu, Yanyuan; Badar, Francesca; Vadgama, Jaydutt V.

Publisher

Multidisciplinary Digital Publishing Institute (MDPI) (ISSN 2077-0383)

Published

2020

Language

EN

Field

Medicine (Health Sciences)